Cost-Effectiveness Analysis of Hepatitis B Immunization in Vietnam: Application of Cost-Effectiveness Affordability Curves in Health Care Decision Making

Value in Health Regional Issues

Volumn 1, Issue 1, 2012, Pages 7-14

  Tu, Hong Anh T ^a,b   de Vries, Robin ^a   Woerdenbag, Herman J ^a   Li, Shu Chuen ^c   Le, Hoa H ^a   van Hulst, Marinus ^a,d   Postma, Maarten J ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b HANOI UNIVERSITY OF PHARMACY   (Viet Nam)

^c UNIVERSITY OF NEWCASTLE   (Australia)

^d MARTINI HOSPITAL   (Netherlands)

Author keywords

Acceptability; Affordability; Cost effectiveness; Incremental cost effectiveness ratio; Quality adjusted life year

Indexed keywords

HEPATITIS B VACCINE;

ARTICLE; BUDGET; CHRONIC HEPATITIS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; GROSS NATIONAL PRODUCT; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RATE; MASS IMMUNIZATION; MEDICAL DECISION MAKING; NEWBORN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; VIET NAM;

EID: 84868294679     PISSN: 22121099     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vhri.2012.03.007     Document Type: Article

References (46)

1. Chen C.J., Yang H.I., Su J., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006, 295:65-73.
2. Beasley R.P., Hwang L.Y., Lin C.C., Chien C.S. Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22 707 men in Taiwan. Lancet 1981, 2:1129-1133.
3. Hepatitis B World Health Organization, [Accessed January 18, 2010]. http://www.who.int/vaccines/en/hepatitisb.shtm/#strategies.
4. Lok A.S., McMahon B.J. Chronic hepatitis B. Hepatology 2001, 34:1225-1241.
5. Beasley R.P. Hepatitis B virus: the major etiology of hepatocellular carcinoma. Cancer 1988, 61:1942-1956.
6. Hipgrave D.B., Nguyen T.V., Vu M.H., et al. Hepatitis B infection in rural Vietnam and the implications for a national program of infant immunization. Am J Trop Med Hyg 2003, 69:288-294.
7. Duong T.H., Nguyen P.H., Henley K., Peters M. Risk factors for hepatitis B infection in rural Vietnam. Asian Pacific J Cancer Prev 2010, 10:97.
8. Holliday S.M., Faulds D. Hepatitis B vaccine: a pharmacoeconomic evaluation of its use in the prevention of hepatitis B virus infection. Pharmacoeconomics 1994, 5:141-171.
9. Tu H.A., Woerdenbag H.J., Kane S., et al. Economic evaluations of hepatitis B vaccination for developing countries. Expert Rev Vaccines 2009, 8:907-920.
10. Review of the expanded program on immunization in Vietnam 2005, World Health Organization.
11. Review of the expanded program on immunization in Vietnam 2010, World Health Organization.
12. Milne A., West D.J., Chinh D.V., et al. Field evaluation of the efficacy and immunogenicity of recombinant hepatitis B vaccine without HBIG in newborn Vietnamese infants. J Med Virol 2002, 67:327-333.
13. Poovorawan Y., Sanpavat S., Pongpunglert W., et al. Long term efficacy of hepatitis B vaccine in infants born to hepatitis B e antigen-positive mothers. Pediatr Infect Dis J 1992, 11:816-821.
14. Lo K.J., Tsai Y.T., Lee S.D., et al. Immunoprophylaxis of infection with hepatitis B virus in infants born to hepatitis B surface antigen-positive carrier mothers. J Infect Dis 1985, 152:817-822.
15. Drain P.K., Nelson C.M., Lloyd J.S. Single-dose versus multi-dose vaccine vials for immunization programmes in developing countries. Bull World Health Organ 2003, 81:726-731.
16. National Institute of Hygiene and Epidemiology, [Accessed January 27, 2010]. http://www.nihe.gov.vn.
17. NIHE/MOH GAVI HSS Proposal 2006, Ministry of Health in Vietnam.
18. Alward W.L., McMahon B.J., Hall D.B., et al. The long-term serological course of asymptomatic hepatitis B virus carriers and the development of primary hepatocellular carcinoma. J Infect Dis 1985, 151:604-609.
19. Liaw Y.F., Sheen I.S., Chen T.J., et al. Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study. Hepatology 1991, 13:627-631.
20. McMahon B.J., Holck P., Bulkow L., Snowball M. Serologic and clinical outcomes of 1536 Alaska natives chronically infected with hepatitis B virus. Ann Intern Med 2001, 135:759-768.
21. McMahon B.J., Alberts S.R., Wainwright R.B., et al. Hepatitis B-related sequelae: prospective study in 1400 hepatitis B surface antigen-positive Alaska native carriers. Arch Intern Med 1990, 150:1051-1054.
22. Yu M.W., Hsu F.C., Sheen I.S., et al. Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. Am J Epidemiol 1997, 145:1039-1047.
23. Fattovich G., Brollo L., Giustina G., et al. Natural history and prognostic factors for chronic hepatitis type B. Gut 1991, 32:294-298.
24. Ikeda K., Saitoh S., Suzuki Y., et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatology 1998, 28:930.
25. Liaw Y.F., Tai D.I., Chu C.M., Chen T.J. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988, 8:493-496.
26. Sherman M., Peltekian K.M., Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 1995, 22:257.
27. De G.J., Fevery J., Lepoutre L. Long-term follow-up of chronic active hepatitis of moderate severity. Gut 1978, 19:510-513.
28. Liaw Y.F., Tai D.I., Chu C.M., et al. Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis: a prospective study. Gastroenterology 1986, 90:263-267.
29. Liaw Y.F., Lin D.Y., Chen T.J., Chu C.M. Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Liver 1989, 9:235-241.
30. Life tables for Vietnam World Health Organization, [Accessed January 14, 2010]. http://apps.who.int/whosis/database/life_tables/.
31. D'Amico G., Morabito A., Pagliaro L., Marubini E. Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci 1986, 31:468-475.
32. Fattovich G., Giustina G., Schalm S.W., et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology 1995, 21:77-82.
33. Fattovich G. Natural history and prognosis of hepatitis B. Semin Liver Dis 2003, 23:47-58.
34. Hung H.F., Chen T.H. Probabilistic cost-effectiveness analysis of the long-term effect of universal hepatitis B vaccination: an experience from Taiwan with high hepatitis B virus infection and Hepatitis B e antigen positive prevalence. Vaccine 2009, 27:6770-6776.
35. Marcellin P., Castelnau C., Martinot-Peignoux M., Boyer N. Natural history of hepatitis B. Minerva Gastroenterol Dietol 2005, 51:63-75.
36. McMahon B.J., Bulkow L., Harpster A., et al. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology 2000, 32(4, Pt 1):842-846.
37. Park K.W., Park J.W., Choi J.I., et al. Survival analysis of 904 patients with hepatocellular carcinoma in a hepatitis B virus-endemic area. J Gastroenterol Hepatol 2008, 23:467-473.
38. Aggarwal R., Ghoshal U.C., Naik S.R. Assessment of cost-effectiveness of universal hepatitis B immunization in a low-income country with intermediate endemicity using a Markov model. J Hepatol 2003, 38:215-222.
39. Stein K., Rosenberg W., Wong J. Cost effectiveness of combination therapy for hepatitis C: a decision analytic model. Gut 2002, 50:253-258.
40. Wong J.B., Bennett W.G., Koff R.S., Pauker S.G. Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs. JAMA 1998, 280:2088-2093.
41. Sutton A.J., Abrams K.R., Jones D.R. An illustrated guide to the methods of meta-analysis. J Eval Clin Pract 2001, 7:135-148.
42. [Accessed August 28, 2009]. http://www.vietcombank.com.vn.
43. Briggs A., Claxton K., Schulpher M. Making decision models probabilistic. Decision Modelling for Health Economic Evaluation 2006, Oxford University Press, Oxford. A. Briggs, K. Claxton, M. Schulpher (Eds.).
44. Sendi P.P., Briggs A.H. Affordability and cost-effectiveness: decision-making on the cost-effectiveness plane. Health Econ 2001, 10:675-680.
45. World health report World Health Organization, [Accessed April 19, 2010]. http://www.who.int/whr/2002/en.
46. Vietnam World Bank, [Accessed May 5, 2010]. http://www.worldbank.org/vietnam.